ReviewHematology. American Society of Hematology. Education Program2016
Sickle cell disease: an inherited thrombophilia.
Review in Hematology. American Society of Hematology. Education Program, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Hydroxyurea in Sickle Cell Disease: Coagulation and Activation in an Observational Study.Clinical medicine insights. Pediatrics · 2026Article
- The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon: An Analytical Cross-Sectional Study.Advances in hematology · 2026Article
- Sickle cell disease: managing thromboembolism.Hematology. American Society of Hematology. Education Program · 2025Review
- Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease.Annals of intensive care · 2025Review
- Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception.Blood advances · 2023Article
- Predisposing Factors and Incidence of Venous Thromboembolism among Hospitalized Patients with Sickle Cell Disease.Journal of clinical medicine · 2023Article
- Article
- Pregnancy outcomes in women with sickle cell disease in California.American journal of hematology · 2023Article
- Clinical Vignettes, Part II: Eyes, Teeth, and Bone.Hematology/oncology clinics of North America · 2022Review
- Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study.Journal of clinical medicine · 2022Article
- Investigation of thrombin generation assay to predict vaso-occlusive crisis in adulthood with sickle cell disease.Frontiers in cardiovascular medicine · 2022Article
- Inflammatory status in pediatric sickle cell disease: Unravelling the role of immune cell subsets.Frontiers in molecular biosciences · 2022Article
- COVID-19 Infection and Acute Pulmonary Embolism in an Adolescent Female With Sickle Cell Disease.Cureus · 2020Article
- The molecular basis for the prothrombotic state in sickle cell disease.Haematologica · 2020Article
- Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.International journal of molecular sciences · 2020Review
- Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals.Mediterranean journal of hematology and infectious diseases · 2020Review
- High incidence of venous thromboembolism recurrence in patients with sickle cell disease.American journal of hematology · 2019Article
- Sickle cells and sickle trait in thrombosis.Blood · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of the hemostatic system occurs in patients with sickle cell disease. The extent to which this activation contributes to sickle cell pathophysiology is uncertain. Clinical trials of anticoagulants or platelet inhibitors have demonstrated the ability to decrease biomarkers of hemostatic activation, but this has generally not resulted in improvement in clinically relevant outcomes. Venous thromboembolism (VTE: deep venous thrombosis and pulmonary embolism) has been until recently an underappreciated complication of sickle cell disease, with incident event and recurrence rates consistent with a strong thrombophilia. There is no strong evidence that management should differ than for other patients with VTE, with the possible exception that secondary prophylaxis be extended regardless of provocation, given the persistent strong thrombophilic state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.